Prospective Clinical Study of Orelabrutinib in Combination With Rituximab (OR) for Primary Marginal Zone Lymphoma (MZL) That Failed or Not Suitable for Local Therapy | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Prospective Clinical Study of Orelabrutinib in Combination With Rituximab (OR) for Primary Marginal Zone Lymphoma (MZL) That Failed or Not Suitable for Local Therapy	B-cell neoplasm, Hemic and Lymphatic Diseases, Lymphoma, B-Cell, Marginal Zone, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, marginal zone lymphoma, neoplasm	Recruiting	Not applicable	2024-07-29		NCT06478472

10 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Chinese PLA General Hospital	238
Fujian Cancer Hospital	114
Guangdong Provincial People's Hospital	164
Jiangxi Provincial Cancer Hospital	33
Nanfang Hospital, Southern Medical University	248
Shanxi Province Cancer Hospital	43
The First Affiliated Hospital of Xiamen University	107
The First Hospital of Jilin University	154
The Second Affiliated Hospital of Dalian Medical University	18
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	319

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Bing, Xu	Xiamen	China	1